30.51MMarket Cap-3077P/E (TTM)
3.5999High3.2800Low65.17KVolume3.4900Open3.4800Pre Close222.68KTurnover0.78%Turnover RatioLossP/E (Static)8.55MShares8.649052wk High11.41P/B30.02MFloat Cap3.050052wk Low--Dividend TTM8.41MShs Float1304.4000Historical High--Div YieldTTM9.19%Amplitude3.0500Historical Low3.4160Avg Price1Lot Size
Dare Bioscience Stock Forum
Benzinga· 4 mins ago
Published data show that responses from 1-month and 24-hour recall patient reported outcome (PRO) instruments were similar and support that either method could be used to assess treatment efficacy in future clinical studies
Longer recall intervals for PRO assessments are less burdensome to cl...
Daré Bioscience Reports Second Quarter 2024 Financial Results and Provides Company Update
Daré Bioscience (NASDAQ: DARE) reported Q2 2024 financial results and provided a company update. Key highlights include:
1. Ongoing enrollment in the OvaprenePhase 3 contraceptive efficacy study across the U.S.
2. Progress on Sildenafil Cream, 3.6% for female sexual arousal disorder, awaiting FDA feedback on Phase 3 study design.
3. Cash and cash equivalents of $16.4 million a...
Daré Bioscience Regains Compliance with Nasdaq Minimum Bid Price Rule
Benzinga
Phase 2b study demonstrated topical Sildenafil Cream, 3.6% improved outcomes among women with female sexual arousal disorder (FSAD), particularly in an exploratory subset of women with FSAD with or without concomitant decreased desire
There are currently no FDA-approved ...
No comment yet